Document:

Fourth Amendment to Amended and Restated License Agreement

 Exhibit 10.28 
 FOURTH AMENDMENT TO THE 
 AMENDED AND RESTATED LICENSE AGREEMENT 
 THIS FOURTH AMENDMENT TO THE AMENDED AND RESTATED LICENSE AGREEMENT (“Amendment”) made as of the 31st day of January, 2006, by and
between VASCULAR GENETICS INC., a Delaware corporation (the “Licensee”) and HUMAN GENOME SCIENCES, INC., a Delaware corporation (“HGS”). 
 WHEREAS, HGS and the Licensee entered into that certain License Agreement, dated as of October 31, 1997 (“Original License Agreement”), whereunder HGS granted to the Licensee an exclusive license
to use the gene Vascular Endothelial Growth Factor 2 in gene therapy treatment of vascular diseases; and 
 WHEREAS, the parties
amended the Original License Agreement in its entirety with that certain Amended and Restated License Agreement, dated February 28, 2001, and further amended such document by a First Amendment to Amended and Restated License Agreement dated
October 10, 2002 and a Second Amendment to Amended and Restated License Agreement dated April 26, 2004, and a Third Amendment to Amended and Restated License Agreement dated March 21, 2005 (collectively “Amended License
Agreement”); and 
 WHEREAS, the parties desire to herein amend the Amended License Agreement. 
 NOW, THEREFORE, for and in consideration of the premises and mutual promises herein contained, and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
  

	1.	The Parties acknowledge that all capitalized terms not otherwise defined herein shall have the meaning ascribed to such terms in the Amended License Agreement.

  

	2.	Section 3.2. Section 3.2 of the Amended License Agreement (minimum use standards) is hereby deleted in its entirety and replaced with the following:

 LICENSEE agrees that it will meet the following minimum use standards either by its own performance or through or in
combination with an affiliate or sublicensee. 
 (a) LICENSEE shall have initiated a Phase IIb or Phase III clinical trial no
later than December 31, 2004. 
 (b) If both a Phase II and Phase III clinical trial are required by FDA, LICENSEE shall
have initiated the Phase III clinical trial no later than six (6) months after the end of the Phase II meeting, but no later than June 30, 2007. 

 (c) LICENSEE shall have filed a BLA for at least one LICENSED PRODUCT no later than
December 31, 2009. 
 LICENSEE will give notice of meeting each milestone within ten (10) business days of its
occurrence. LICENSEE will provide semi-annual updates to HGS on the clinical trial progress. For purposes of the above milestone, initiate shall mean when the first patient is dosed with CLINICAL TRIAL MATERIAL. If FDA imposes unexpected
requirements unrelated to actions by LICENSEE, LICENSEE and HGS will negotiate in good faith extension of these milestones. 
  

	3.	Appendix A of the Amended License Agreement is hereby deleted in its entirety and replaced with Schedule A attached hereto. 

  

	4.	Except as otherwise expressly stated herein, all provisions of the Amended License Agreement remain in full force and effect. 

  

	5.	This Amendment may be signed in one or more counterparts, which when taken together shall constitute one and the same Amendment. 

 IN WITNESS WHEREOF, the parties have executed and delivered this Amendment as of the date first written above. 
  

			
	HGS:
	
	HUMAN GENOME SCIENCES, INC.
		
	By:	 	 /s/ James H. Davis, Ph.D.
  

	Name:	 	 James H. Davis, Ph.D.

	Title:	 	 Executive Vice President

	
	LICENSEE:
	
	VASCULAR GENETICS INC.
		
	By:	 	 /s/ Richard E. Otto
  

	Name:	 	 Richard E. Otto

	Title:	 	 Chief Executive Officer

 Schedule A 
  

					
	 Application Title
	  	U.S. Serial No.	  	Patent No.
	Vascular Endothelial Growth Factor 2	  	08/207,550	  	
			
		  	08/824,996	  	5,935,820
			
		  	09/257,918	  	
			
		  	09/618,451	  	
			
		  	10/060,523	  	
			
		  	10/853,232	  	
			
	Vascular Endothelial Growth Factor 2	  	08/465,968	  	6,608,182
			
		  	10/127,551	  	
			
		  	10/023,584	  	
			
	Vascular Endothelial Growth Factor 2	  	11/211,724	  	
			
	Vascular Endothelial Growth Factor 2	  	08/999,811	  	5,932,540
			
	Vascular Endothelial Growth Factor 2	  	09/219,442	  	
			
	Vascular Endothelial Growth Factor 2	  	09/257,272	  	
			
	Vascular Endothelial Growth Factor 2	  	11/153,880	  	
			
	Vascular Endothelial Growth Factor 2	  	09/042,105	  	6,040,157
			
		  	09/935,726	  	
			
		  	09/438,538	  	
			
		  	11/067,015	  	
			
	Vascular Endothelial Growth Factor 2 and Compositions	  	09/623,725	  	
			
		  	10/084,488	  	6,734,285
			
		  	10/696,002	  	
			
	Vascular Endothelial Growth Factor 2	  	09/107,997	  	
			
	Vascular Endothelial Growth Factor 2	  	11/233,119	  	
			
	Vascular Endothelial Growth Factor 2	  	09/921,143	  	
			
	Vascular Endothelial Growth Factor 2	  	11/249,422	  	
			
	Vascular Endothelial Growth Factor 2	  	09/499,468	  	
			
	Vascular Endothelial Growth Factor 2	  	11/078,507Material Transfer Agreement

 Exhibit 10.33 
  

 MATERIAL TRANSFER AGREEMENT 
 (Critical Limb Ischemia Trial) 
 By and Between 
 CORAUTUS GENETICS INC., 
 A Delaware
Corporation, 
 And 
 CARITAS ST.
ELIZABETH’S MEDICAL CENTER OF BOSTON, INC., 
 A Massachusetts Not For Profit Corporation 
 January 6, 2006 
  

 MATERIAL TRANSFER AGREEMENT 
 THIS MATERIAL TRANSFER AGREEMENT is entered into, effective as of January 6, 2006, by and between CORAUTUS GENETICS INC., a Delaware
Corporation (“Corautus”), and CARITAS ST. ELIZABETH’S MEDICAL CENTER OF BOSTON, INC., a Massachusetts Not For Profit Corporation (“Recipient”). 
 W I T N E S S E T H: 
 WHEREAS, Corautus licenses intellectual property rights to the vascular endothelial growth factor-2 gene, referred to as VEGF-2, and has produced proprietary naked plasmid DNA encoding for VEGF-2, including plasmid DNA sometimes
referred to as phVEGF-2 or pVGI.1(VEGF2); 
 WHEREAS, Recipient desires to use the VEGF-2 gene plasmid DNA material and related
documentation for the limited purpose of the Research Study as hereinafter defined; 
 WHEREAS, Corautus has agreed to transfer to
Recipient, and Recipient has agreed to receive from Corautus, certain quantities of Original Biological Materials, as defined below, and related documentation for such limited purposes pursuant to the terms and conditions set forth in this
Agreement; and 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 ARTICLE I

 DEFINITIONS AND INTERPRETATION 
 1.01 Definitions. For purposes of this Agreement, the following capitalized terms shall have the following respective means: 
 (a) “Act” means the United States Food, Drug and Cosmetic Act, as may be amended from time to time, to the extent applicable. 
 (b) “Additional Clinical Trials” means Phase II, Phase III or any other human clinical trial testing the safety and efficacy of the Biological Materials for the treatment of peripheral
artery disease. 
 (c) “AE” means, with respect to use of the Biological Material, any adverse event within the meaning of
applicable FDA regulations, and including, without limitation, any unfavorable and unintended sign (including, without limitation, an 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 

 abnormal laboratory finding), exacerbation of a pre-existing condition, intercurrrent illness, drug interaction,
significant worsening of a disease under investigation or treatment, significant failure of expected pharmacological or biological action, or symptom or disease temporally associated with the use of such Biological Material, which event is
associated with the use of the Biological Material in the Research Study. 
 (d) “Agreement” means this Material Transfer
Agreement, together with all Exhibits attached hereto and all amendments hereto executed by all Parties. 
 (e) “Biological
Materials” means the vascular endothelial growth factor-2 gene referred to as “VEGF-2” and proprietary naked plasmid DNA encoding for VEGF-2, including the plasmid DNA sometimes referred to as “phVEGF-2” or
“pVGI.1(VEGF2),” together with any Progeny, Derivatives and Modifications therefrom. 
 (f) “Corautus Confidential
Information” shall mean all Documentation and any other data or information that is of value to Corautus and is not generally known to competitors of Corautus. To the extent consistent with the foregoing, Confidential Information includes
information or data that (i) concerns the operations, facilities, manufacturing, clinical trials, pre-clinical studies, regulatory affairs and compliance, protocols, bench work, assay development, methodology, pricing, plans, affairs and
businesses of Corautus and the financial affairs of Corautus, (ii) constitutes trade secrets under applicable law, or (iii) is marked confidential, restricted, proprietary or with a similar designation. Confidential Information also
includes any information of the type described in this paragraph that Corautus obtains from another Person that Corautus or such other Person treats as proprietary or designates as confidential information, whether or not owned or developed by
Corautus or such other Person. Notwithstanding the foregoing, such term shall not include any materials or information of the types specified above to the extent that such materials or information: (i) are or become generally known by other
Persons engaged in the same business or activities in which Corautus utilized, developed or otherwise acquired such information or publicly known; (ii) are known to Recipient prior to receipt thereof and without any restrictions on disclosure
in favor of Corautus; or (iii) are furnished to other Persons by Corautus with no restriction on disclosure. 
 (g) “Corautus
Field of Use” means the use of Biological Materials for treating peripheral artery disease including, without limitation, critical limb ischemia. 
 (h) “Corautus Trials” means human clinical trials sponsored by Corautus. 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -2- 

 (i) “Current Protocol” means the FDA approved protocol for the Research Study as amended
through Amendment 3, which Amendment 3 was submitted to the FDA on or about May 31, 2005. 
 (j) “Derivative”
means a substance which constitutes an unmodified functional sub-unit or product expressed by the Biological Materials, including, but not limited to, genes and regulatory sequences and proteins expressed by DNA or RNA. 
 (k) “Documentation” means the documents and information transferred by Corautus to Recipient for purposes of the Research Study
described herein. 
 (l) “FDA” means the United States Food and Drug Administration. 
 (m) “Final Protocol” means the FDA approved protocol for the Research Study together with all amendments submitted to and approved by
the FDA. 
 (n) “Intellectual Property” means all intellectual property rights, including (i) United States and other
national patents and patent applications, divisions, continuations, continuations-in-part, reissues, renewals, reexaminations, requests for continued examination, supplemental registrations or extensions thereof, (ii) trademarks, whether
registered or unregistered and applications for registration thereof, (iii) copyrights, whether registered or unregistered and applications for registration thereof, and (iv) trade secrets, know-how, technology, proprietary information and
data, including formulae, procedures, plans, methods, processes, specifications, models, protocols, techniques and experimentation, and design, testing and manufacturing data, and products, compositions, and procedures. 
 (o) “Inventions” means findings, discoveries, inventions, additions, modifications, formulations, variations, enhancements, refinements
or derivative works. 
 (p) “Joint Invention” means any Invention except a Recipient Invention or a VEGF Invention, whether
patentable or not, first conceived and/or reduced to practice under the Research Study which could be described in a patent application, if one were to be filed, naming one or more employees and/or agents of Recipient and one or more employees
and/or agents of Corautus as joint inventors as determined under U.S. patent laws 
 (q) “Law” means the Act and any other
United States or non-United States federal, national, supranational, state, provincial, local or similar statute, law, ordinance, regulation, rule, code, order, rule of law or requirement, to the extent applicable. 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -3- 

 (r) “License Agreement” means the License Agreement between Recipient and Vascular
Genetics, Inc., a wholly owned subsidiary of Corautus, dated February 10, 1999 as it may be amended from time to time, and sublicenses granted thereunder. 
 (s) “Modification” means any material substantially based on, containing or incorporating a substantial element of the Biological Material, or any materials which are not new or not obviously distinct
from the Biological Material. 
 (t) “Original Biological Materials” means the Biological Materials provided to Recipient
under this Agreement, together with any Progeny, Derivatives and Modifications therefrom. 
 (u) “Party” or
“Parties” means individually and collectively, respectively, Corautus and Recipient. 
 (v) “Person” means
any natural person, corporation, limited liability company, partnership, limited partnership, joint venture, association, trust, firm, organization, governmental authority or other entity of any kind or nature. 
 (w) “Progeny” means any unmodified descendant from the Biological Material, including cell from cell, or organism from organism.

 (x) “Recipient Confidential Information” shall mean all Documentation and any other data or information that is of value
to Recipient and is not generally known to competitors of Recipient. To the extent consistent with the foregoing, Confidential Information includes information or data that (i) concerns the operations, facilities, manufacturing, clinical
trials, pre-clinical studies, regulatory affairs and compliance, protocols, bench work, assay development, methodology, pricing, plans, affairs and businesses of Recipient and the financial affairs of Recipient, (ii) constitutes trade secrets
under applicable law, or (iii) is marked confidential, restricted, proprietary or with a similar designation. Confidential Information also includes any information of the type described in this paragraph that Recipient obtains from another
Person that Recipient or such other Person treats as proprietary or designates as confidential information, whether or not owned or developed by Recipient or such other Person. Notwithstanding the foregoing, such term shall not include any materials
or information of the types specified above to the extent that such materials or information: (i) are or become generally known by other Persons engaged in the same business or activities in which Recipient utilized, developed or otherwise
acquired such information or publicly known; (ii) are known to Recipient prior to receipt thereof and without any restrictions on disclosure in favor of Recipient; or (iii) are furnished to other Persons by Recipient with no restriction on
disclosure. 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -4- 

 (y) “Recipient Patents” means those United States or foreign patents and/or applications
listed on Exhibit B hereto as amended and modified from time to time by Recipient which such Exhibit is hereby incorporated herein by reference, the inventions disclosed therein, and any divisions, reissues, continuations, continuations in
part or extensions relating or corresponding thereto, and disclosed in foreign patent application corresponding thereto. 
 (z)
“Recipient Invention” means Inventions relating solely to the use of vascular endothelial growth factors for the treatment of critical limb ischemia conceived and/or reduced to practice during the Research Study by use
of the Original Biological Material, to the extent any patent applications or patents directed to such Inventions are not a Recipient Patent. 
 (aa) “Research Study” means the Phase 1 clinical trial under IND BB-IND 11948 entitled “A Randomized Double-Blind, Placebo-Controlled, Dose-Escalating Study of Intramuscular Vascular Endothelial Growth Factor 2 Gene
Transfer in Patients with Moderate or High-Risk Critical Limb Ischemia” funded, in part, by a grant received by Recipient from the National Institutes of Health, and is pursuant to NIH Protocol No. 0408-671. The Research Study will be
conducted at the facility of Recipient and through subinvestigators at clinical sites listed on Exhibit C. 
 (bb)
“Research Study Data” means the data generated under the Research Study. 
 (cc) “VEGF Invention” means
Inventions relating solely to the Original Biological Materials, including but not limited to manufacturing, use or techniques thereof. Specifically excluded from this definition are Recipient Inventions. 
 1.02 Interpretation and Construction. 
 (a)
References. Whenever reference is made in this Agreement to any Article, Section or Exhibit, such reference shall be deemed to apply to the specified Article or Section of, or the specified Exhibit to, this Agreement. The words
“hereof,” “herein,” “hereby,” “hereinafter,” “hereunder” and words of similar import shall refer to material set forth in this Agreement as a whole and not to any particular subdivision unless
expressly so limited. 
 (b) Headings. Article, Section and other headings contained in this Agreement are inserted for convenience
only and shall not be construed to define, interpret, describe or limit the scope, extent or intent of this Agreement or any provision hereof. 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -5- 

 (c ) Gender and Number. Where the context requires, the use of a pronoun of one gender or the
neuter is to be deemed to include a pronoun of the appropriate gender, singular words are to be deemed to include the plural, and vice versa. 
 (d) Including. Words of inclusion shall not be construed as terms of limitation herein, so that references to “included” matters shall be regarded as non-exclusive, non-characterizing illustrations. 
 ARTICLE II 
 SUPPLY OF MATERIALS AND
SCOPE OF USE 
 2.01 Supply of Original Biological Materials and Documentation. Corautus shall supply to Recipient the Original Biological
Materials and the Documentation in such quantity and from such sources as are identified in Exhibit A attached hereto for the limited purposes stated herein; provided, however, that Corautus in its sole discretion may substitute Original
Biological Materials from other sources. 
 2.02 Scope of Use. Recipient may use the Original Biological Materials and Documentation only at its
facilities and at the facilities listed on Exhibit C for the sole purpose of conducting the Research Study described herein. Except as expressly permitted hereby, Recipient shall not use any Original Biological Materials or Documentation
in human subjects in any manner or for commercial purposes, including the use of such Original Biological Materials or Documentation to produce or manufacture products for sale. No Original Biological Materials or Documentation may be exported or
otherwise transferred outside of the United States. Recipient may use the Original Biological Materials solely for the purpose of injecting in the limbs of patients as part of the Research Study and may not modify or alter the Original Biological
Materials in any way or conduct any research with the Original Biological Materials other than the Research Study. 
 2.03 Control and Use of Original
Biological Materials. The principal investigator named in the Research Study shall administer the Original Biological Materials only to patients under his personal supervision or under the supervision of an investigator responsible to him.

 2.04 Compliance with Laws. 
 (a)
Original Biological Materials. Recipient shall use, handle, store and dispose of the Original Biological Materials in a safe manner consistent with the Handling Instructions set forth in Exhibit D-3 and in compliance with all
Laws, 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -6- 

 including, without limitation, all requirements and guidelines of the National Institutes of Health and the FDA and all
requirements relating to human and animal subjects and recombinant DNA. Recipient shall also comply with all Laws relating to the delivery of Original Biological Materials provided hereunder. 
 (b) Research Study. Recipient shall fully and timely discharge all obligations under all Laws or requirements of the FDA or National Institutes of
Health with respect to the Research Study. 
 2.05 Records. 
 (a) Study Records. The Recipient and the principal investigator shall, and shall cause all investigators to, prepare and maintain Original Biological Materials records in accordance with the protocol approved
for the Research Study and applicable Law. Properly organized Research Study records must be maintained and assistance provided for routine inspections and audits of such records by Corautus’ authorized representatives at mutually agreed upon
reasonable times, including portions of pertinent records for all patients in the Research Study. Without limiting the generality of the foregoing, Recipient shall maintain a clinical trial material accountability log to maintain records of the
Original Biological Materials. The cost of these inspections shall be borne by Corautus. 
 (b) Access and Reference. Recipient agrees
that Corautus may reference and access the data in the Research Study to the extent requested by Corautus to support the Corautus Trials under IND 7961 and 8205, and Recipient will advise the FDA in writing of such rights of reference and
access when requested by Corautus. Recipient will also, at Corautus expense upon Corautus’ reasonable request make available its personnel involved in the Research Study, to the extent such personnel are under the control of Recipient, to
answer questions about the Research Study. The timing, duration and place of such availbility, shall be mutually agreed by the parties in advance. Except as permitted above, Corautus must obtain the prior written consent of Recipient to reference
and access the data in the Research Study to support Corautus Trials, for which timely consent shall not be unreasonably withheld. 
 (c)
Research Study Data. Recipient shall provide Corautus, promptly upon Corautus’ request, with a full and complete copy of the Research Study Data. 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -7- 

	2.06	Reporting Obligations. 

 (a) Adverse Events.
Recipient shall (i) adhere to all requirements of applicable Laws which relate to the reporting and investigation of AEs in the Research Study and keep Corautus informed of such matters, (ii) promptly inform Corautus of any material safety
or health incidents related to the Original Biological Materials in the Research Study, and (iii) promptly inform Corautus upon becoming aware of any unusual or unexpected reactions or events, malfunctions, safety or efficacy of or attributable
to the Original Biological Materials and/or any regulatory authority action related thereto. 
 (b) Drug Safety Information. Recipient
shall immediately provide Corautus with drug safety requests from all governmental and other regulatory authorities with respect to the Original Biological Materials. Proposed answers by Recipient affecting Original Biological Materials will be
provided to Corautus before submission, and the Parties shall cooperate with respect to such answers. 
 (c) Regulatory Actions.
Recipient shall advise Corautus of any regulatory action of which it is aware which would affect the Original Biological Materials. 
 (d)
Governmental Inspection. Recipient shall advise Corautus of any governmental communication, inspection or report relating to the Original Biological Materials which it is aware and which might reasonably be expected to affect the Original
Biological Materials. Any response to a regulatory notice relating to the Original Biological Materials or such Law shall be prepared jointly by the Parties. 
 2.07 Nature of Original Biological Materials. All Original Biological Materials provided hereunder should be considered experimental in nature, may contain hazardous properties and should be handled by Recipient with appropriate
safety precautions, including, without limitation, as provided in Section 2.03 herein. CORAUTUS HEREBY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE ORIGINAL BIOLOGICAL MATERIALS AND DOCUMENTATION,
INCLUDING, ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. Notwithstanding the foregoing, Corautus warrants that all Original Biological Materials meet the Certificate of Analysis as set forth in
Exhibit D or any other similar certificate of analysis provided by Corautus in connection with Original Biological Materials. 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -8- 

 2.08 Performance. Recipient agrees to complete the Research Study within approximately ** months of the date
hereof in accordance with the Final Protocol, which Recipient agrees will also be substantially in accordance with the Current Protocol. In the event that unexpected technical or regulatory difficulties or something outside of the control of
Recipient makes completion of the Research Study not achievable within this time period, Corautus and Recipient will renegotiate a replacement date in good faith. For the avoidance of doubt, if Recipient is unable to meet this date, Corautus will
not be entitled to terminate the Agreement unless it can be demonstrated that Recipient has not used good faith and reasonable efforts towards completion of the Research Study. 
 2.09 Additional Clinical Trials. 
 (a) For a period of ** from the date of the Agreement, the Parties
agree that they will cooperate in good faith to provide Recipient with the opportunity to be a primary clinical site in any Additional Clinical Trial sponsored by Corautus, subject to applicable law and reasonable qualifications. Corautus shall
permit Recipient to state in its marketing and similar materials that Recipient is Corautus’ premier clinical site in such Additional Clinical Trials if Recipient is actively participating in such Additional Clinical Trial as an investigator.
Notwithstanding the foregoing, because the details, timing and conditions of any Additional Clinical Trial cannot be predicted, Corautus shall not be obligated to Recipient as a clinical site for, and Recipient shall not be obligated to participate
as a clinical site in any Additional Clinical Trial. 
 (b) Recipient will not sponsor or participate in Additional Clinical Trials other
than those sponsored by Corautus for a period of ** from the date hereof. 
 ARTICLE III 
 LICENSES AND INTELLECTUAL PROPERTY 
 3.01 Limited
License. Subject to the terms and conditions of this Agreement, Corautus hereby grants to Recipient a non-exclusive, non-transferable and royalty-free license (without the right to sublicense) to use the Original Biological Materials and
Documentation for the sole purpose of conducting the Research Study described herein. Except as specifically provided in this Section 3.01, no express or implied licenses or other rights are provided to Recipient under any Intellectual Property
rights of Corautus. Without limiting the foregoing, no express or implied license or other rights are provided to use the Original Biological Materials and Documentation for any purpose other than as specifically allowed in Section 2.02 herein.

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as provided in this Agreement. 
  

	**	Confidential Treatment Requested 

  

 -9- 

 3.02 Transfers and Sublicenses. Recipient shall retain physical control of the Original Biological Materials and
Documentation and shall not sell, license, distribute or otherwise transfer or provide access to any Original Biological Materials or Documentation, or any portion thereof, to any other Person without the prior written consent of Corautus. The
limited license granted pursuant to Section 3.01 herein may not be sublicensed to any other Person. Notwithstanding the foregoing, portions of the Original Biological Materials may be provided by Recipient to subinvestigators listed on
Exhibit C to use in its Research Study, but Recipient shall nevertheless be responsible to Corautus for all obligations hereunder. 
  

	3.03	Ownership and Inventions. 

 (a) Pre-Existing
Corautus Rights. As between the Parties, Corautus retains ownership of all right, title and interest in and to the Original Biological Materials, Documentation, Corautus Confidential Information and all Intellectual Property of Corautus, subject
only to the limited license granted in Section 3.01 herein. 
 (b) Pre-Existing Recipient Rights. As between the Parties,
Recipient retains ownership of all right, title and interest in and to Recipient Confidential Information, Recipient Patents, Recipient Invention, Research Study, and all Intellectual Property of Recipient, subject only to the right of first refusal
granted in Section 3.03(g) herein and any applicable rights under the License Agreement. 
 (c) Joint Inventions by Both Parties.
If Joint Invention is conceived, discovered or reduced to practice by the Parties, the Parties agree to reasonably assist each other in obtaining patent protection for any such Joint Invention. Notwithstanding the foregoing, the parties shall
negotiate in good faith an agreement covering the terms and conditions under which any such Joint Invention shall be protected and exploited, including but not limited to, which party shall control protection and exploitation of such Joint
Invention, the sharing of expenses relating to any patent applications that may be filed covering such Joint Invention and any profits and royalties in respect of such Joint Invention. 
 (d) New Inventions by A Party. Each Party shall retain all right, title and interest in any and all Intellectual Property in and to Inventions,
other than VEGF Inventions or Recipient Inventions, conceived, discovered or reduced to practice solely by that Party pursuant to performance under this Agreement. 
 (e) Ownership of VEGF Inventions. Notwithstanding anything herein to the contrary, regardless of which Party discovered or reduced to practice any VEGF Invention, Corautus shall own all right, title and
interest in and to all VEGF Inventions, and Recipient hereby assigns to Corautus all of its right, title and interest in and to such VEGF Inventions and agrees to execute any documents necessary to record or otherwise perfect such assignment.

  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -10- 

 (f) Ownership of Recipient Inventions. Notwithstanding anything herein to the contrary, regardless
of which Party discovered or reduced to practice any Recipient Invention, Recipient shall own all right, title and interest in and to all Recipient Inventions, and Corautus hereby assigns to Recipient all of its right, title and interest in and to
such Recipient Inventions and agrees to execute any documents necessary to record or otherwise perfect such assignment. 
 (g) Recipient
Inventions: Option. Recipient hereby grants to Corautus the right and option to acquire an exclusive, worldwide royalty bearing license with right to sublicense under Recipient Inventions in the Corautus Field of Use for the life of any
patent to be issued with respect to the Recipient Inventions. There shall be no milestone payments, and the royalty under any such license shall not exceed ** of net sales. This option may be exercised as to a Recipient Invention at any time during
the one year period commencing on the date Recipient gives written notice to Corautus that Recipient has filed a patent application covering such Recipient Invention. 
 3.04 Integrity of Original Biological Materials. Except as specifically authorized by Corautus as part of the Research Study described herein, Recipient shall not analyze, or have analyzed, the composition or
formulation of any Original Biological Materials. 
 3.05 Protection of Corautus Confidential Information. 
 (a) Confidentiality of Corautus Confidential Information. During the Term of this Agreement and for a period of seven (7) years after the
termination of this Agreement, whether at the instance of any Party, Recipient shall not, except as expressly authorized or directed by Corautus, use, copy, or disclose, or permit any unauthorized Person access to, any Corautus Confidential
Information; provided, however, Recipient may disclose Corautus Confidential Information to such of its employees and to subinvestigators listed on Exhibit C who have a need to know in connection with the performance of the Research
Study described herein and have executed nondisclosure agreements obligating such Persons to keep the Corautus Confidential Information confidential in accordance herewith, or are otherwise bound by similar confidentiality obligations. Failure to
mark any of the Corautus Confidential Information as confidential shall not affect its status as Corautus Confidential Information under this Agreement. 
 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as provided in this Agreement. 
  

	**	Confidential Treatment Requested 

  

 -11- 

 (b) Disclosure Required by Legal Process. Any disclosure by Recipient of Corautus Confidential
Information required by legal process or requirement of a governmental regulatory authority shall only be made to the extent required by legal process or such governmental authority and after providing Corautus with prompt notice thereof in order to
permit Corautus to seek an appropriate protective order or exemption. 
 (c) Return of Corautus Confidential Information. Upon the
termination of this Agreement for any reason, whether at the instance of any Party, Recipient shall return to Corautus, upon demand, all Documentation and other Corautus Confidential Information in its possession or, upon demand, destroy such
Corautus Confidential Information and provide a duly authorized and executed certificate to Corautus of such destruction. 
 3.06 Protection of Recipient
Confidential Information. 
 (a) Confidentiality of Recipient Confidential Information. Subject to the provisions of
Section 2.05(b) hereof, during the Term of this Agreement and for a period of seven (7) years after the termination of this Agreement, whether at the instance of any Party, Corautus shall not, except as expressly authorized or directed by
Recipient, use, copy, or disclose, or permit any unauthorized Person access to, any Recipient Confidential Information; provided, however, Corautus may disclose Recipient Confidential Information to such of its employees and investigators who have a
need to know in connection with the performance of the Corautus Trials IND 7961 and 8205 and have executed nondisclosure agreements obligating such Persons to keep the Recipient Confidential Information confidential in accordance herewith, or
are otherwise bound by similar confidentiality obligations. Failure to mark any of the Recipient Confidential Information as confidential shall not affect its status as Recipient Confidential Information under this Agreement. 
 (b) Disclosure Required by Legal Process. Any disclosure by Corautus of Recipient Confidential Information required by legal process or
requirement of a governmental regulatory authority shall only be made to the extent required by legal process or such governmental authority and after providing Recipient with prompt notice thereof in order to permit Recipient to seek an appropriate
protective order or exemption. 
 (c) Return of Recipient Confidential Information. Subject to the provisions of Section 2.05(b)
hereof, upon the termination of this Agreement for any reason, whether at the instance of any Party, Corautus shall return to Recipient upon demand, all Documentation and other Recipient Confidential Information in its possession or, upon demand,
destroy such Recipient Confidential Information and provide a duly authorized and executed certificate to Recipient of such destruction. 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -12- 

 3.07 Publications and Publicity. 
 (a) Recipient Publications. In the event Recipient or any of its investigators, desires to publish any previously unpublished data or patient summaries concerning the Research Study or any results of the
Research Study, whether by means of publication in scientific journals or at seminars or conferences or otherwise, the Recipient or such investigator shall provide Corautus with at least sixty (60) days written notice prior to the proposed date
of submission of such data or information for publication, which notice shall be accompanied by the proposed publication (e.g., abstract, manuscript, or grant application). Recipient will consider in good faith any comments that Corautus may
have regarding any proposed publication. Notwithstanding the foregoing, in the event the Research Study has been performed so that it does not substantially comply with the Current Protocol, Recipient agrees that it will not publish any data
concerning the Biological Materials without the prior written consent of Corautus. 
 (b) Corautus Publications. In the event Corautus
desires to publish any previously unpublished data or patient summaries concerning the Research Study or any results of the Research Study and obtained under paragraph 2.05(b) above, whether by means of publication in scientific journals or at
seminars or conferences or otherwise, Corautus shall provide Recipient with at least sixty (60) days written notice prior to the proposed date of submission of such data or information for publication, which notice shall be accompanied by the
proposed publication (e.g., abstract, manuscript, or grant application). Corautus will consider in good faith any comments that Recipient may have regarding any proposed publication. 
 (c) Publicity and Marks. Neither Party may use any name, trade name, logo, trademark or service mark of the other part in any form or publicity in
connection with the Research Study or this Agreement without the prior written consent of the other party. 
 ARTICLE IV 
 TERM AND TERMINATION 
 4.01 Term. This
Agreement shall be effective as of the date hereof, and shall continue in effect until the Research Study is concluded and all obligations of the Parties to the other with respect to the Research Study and the Agreement are fulfilled.

 4.02 Remedies for Default. If either Party breaches this Agreement and does not cure such breach within sixty (60) days of receipt of written
notice thereof from the other Party, any non-breaching Party may seek any and all remedies available at law or in equity. 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -13- 

 4.03 Disposal of Original Biological Materials. Upon the termination of the Research Study, Recipient shall
immediately discontinue its use of Original Biological Materials and Documentation and destroy or return, at Corautus’s request, all quantities of Original Biological Materials and Documentation in its possession. 
 4.04 Indemnification; Limitation of Damages. Recipient shall indemnify, hold harmless and defend Corautus, its affiliates and their respective employees, agents,
officers and directors (hereinafter collectively, the “Corautus Indemnitees”), from and against any and all claims or suits arising out of the Research Study resulting from any gross negligence or intentional wrongful act or omission of
the Recipient or any of its employees. This indemnification shall include, but not be limited to, reimbursement of all costs, including reasonable attorneys’ fees, incurred in the defense of the claim or suit and any judgment or settlement.
Recipient’s obligation to defend and indemnify the Corautus Indemnitees shall be subject to the requirements that: (a) Corautus Indemnitees shall notify the Recipient promptly of any claim; provided, however, delay in notice shall be
excused if Recipient is not prejudiced by the delay, (b) the Corautus Indemnitee shall cooperate fully in the handling of the claim, (c) the Recipient shall have, at its discretion, sole control of the defense of such claim, provided
Recipient first acknowledges in writing its obligations to indemnify the Corautus Indemnitee and provided further that no settlement of a Third Party claim (other than a monetary settlement) may be effected by Recipient that has an adverse impact
upon Corautus without Corautus’ prior written consent which consent shall not be unreasonably withheld or delayed, and (d) the Recipient shall not be responsible for any costs or expenses associated with the settlement of any claim, demand
or lawsuit made by a Corautus Indemnitee without the prior written consent of the Recipient. Notwithstanding the foregoing, Corautus Indemnitee shall have the right at any time to employ separate counsel at Corautus’ expense and to control its
own defense of any such claim or proceeding, if a conflict or potential conflict existing between the Corautus Indemnitee and the Recipient would make such separate representation advisable under applicable standards of professional conduct.
Further, notwithstanding the foregoing, the Recipient’s liability for claims for indemnification as provided herein shall be satisfied only through, and to the extent of payments or reimbursements resulting from, Recipient’s insurance
coverage. 
 Corautus will not be liable to Recipient for any losses suffered by or against Recipient arising from the Original Biological Materials or this
Agreement, except to the extent caused by the gross negligence or willful misconduct of Corautus. 
 4.05 Limitation of Damages. IN NO EVENT SHALL
EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY INDEMNIFIED PERSON FOR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL OR INDIRECT DAMAGES, 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -14- 

 INCLUDING LOSS OF PROFITS OR REVENUE, REGARDLESS OF ANY KNOWLEDGE OR NOTIFICATION OF THE LIKELIHOOD OF SUCH DAMAGES
OCCURRING. 
 ARTICLE V 
 NOTICES 
 5.01 Notices. Except as otherwise provided herein, any notice, request, demand, instruction or other document to be given
hereunder by either Party hereto to the other Party hereto shall be in writing and sent by facsimile or delivered personally or sent by registered or certified mail (including by overnight courier or express mail service), postage or fees prepaid,
and addressed as set forth below or such other address for a Party as shall be specified by like notice. 
  

			
	if to Corautus:	  	 Corautus Genetics Inc.
 75 Fifth Street, NW,
Suite 313
 Atlanta, GA 30308
 Fax: (404) 526-6218

Attention: Chief Executive Officer

		
	if to Recipient:	  	 Caritas St. Elizabeth’s Medical Center of Boston, Inc.
 736 Cambridge Street
 Boston, MA 02135
 Fax:
617-562-7142
 Attention: Mark Clement

		
	with a Copy to:	  	 The Rogers Law Firm
 100 Cambridge Street
 20th Floor, Suite 2000
 Boston, MA 02114
 Facsimile No.: 617-723-1180
 Attn: Wilson D. Rogers, Jr., Esq.

 Any notice sent by facsimile shall be deemed to have been duly given to the Party to whom it is
sent upon written confirmation of receipt, provided that a copy of such fax is delivered personally or mailed to the recipient within one business day of the date of the fax, in the manner herein provided. Any notice which is delivered personally in
the manner provided herein shall be deemed to have been duly given to the Party to whom it 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -15- 

 is directed upon actual receipt by such Party or the office of such Party. Any notice which is addressed and mailed in
the manner herein provided shall be conclusively presumed to have been duly given to the Party to which it is addressed at the close of business, local time of the recipient, on the fourth business day after the day it is so placed in the mail or,
if earlier, the time of actual receipt. 
 ARTICLE VI 
 MISCELLANEOUS 
 6.01 Entire Agreement. This Agreement (including its Exhibits, which are incorporated herein)
constitutes the entire agreement between the Parties and supersedes any prior understanding or agreement between them respecting the Research Study. 
 6.02 Amendment. No amendment, modification or alteration of the terms or provisions of this Agreement shall be binding unless the same shall be in writing and duly executed by both Parties hereto. 
 6.03 No Waiver. No waiver of any provision hereof will be valid or binding on the Parties hereto, unless such waiver is in writing and signed by or on behalf of
the Parties hereto, and no waiver on one occasion shall be deemed to be a waiver of the same or any other provision hereof in the future. 
 6.04
Severability. In case any one or more of the provisions contained in this Agreement should be found by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect against either Party, such invalidity, illegality, or
unenforceability shall only apply to such Party in the specific jurisdiction where such judgment shall be made, and the validity, legality, and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired
thereby, except that this Agreement shall not be reformed in any way that will deny to any Party the essential benefits of this Agreement or materially alter its obligations hereunder, unless such Party waives in writing its rights to such benefits
or agrees in writing to a modification of its obligations. 
 6.05 Parties Bound by Agreement; Successors and Assigns. The terms, conditions and
obligations of this Agreement shall inure to the benefit of and be binding upon the Parties hereto and the respective successors and assigns thereof. Neither Party may assign its rights, duties or obligations hereunder or any part thereof to any
other Person without the prior written consent of the other Party. 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -16- 

 6.06 No Third-Party Beneficiaries. With the exception of the Parties to this Agreement, there shall exist no right
of any Person to claim a beneficial interest in this Agreement or any rights occurring by virtue of this Agreement. 
 6.07 Survival. The
Parties’ respective obligations hereunder which by their nature would continue beyond the termination, cancellation or expiration of this Agreement. 
 <Signatures on Following Page> 
  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -17- 

 IN WITNESS WHEREOF, the Parties hereto have signed this Agreement the day and year first written
above. 
  

			
	CORAUTUS GENETICS INC.,
		
	By:	 	 /s/ Richard E. Otto

		 	Richard E. Otto
		 	Chief Executive Officer & President
	
	CARITAS ST. ELIZABETH’S MEDICAL
	CENTER OF BOSTON, INC.
		
	By:	 	 /s/ Deanna Citerne

		 	Director, Research Administration

  

 CONFIDENTIAL AND PROPRIETARY 
 Contains Confidential and/or Proprietary Information. 
 May not be disclosed except as
provided in this Agreement. 
 -18- 

 EXHIBIT A 
 Clinical Materials 
 ** 
  

	**	Confidential Treatment Requested 

 EXHIBIT B 
 RECIPIENT PATENTS 
 Title of Invention: Method for Treating Ischemic Tissue 
 Inventor: Jeffrey M. Isner 
 Assignee: Caritas St.
Elizabeth’s Medical Center of Boston, Inc. 
 US Patent Number 6,121,246, issued 9/19/00 

 EXHIBIT C 
 LIST OF CLINICAL SITES 
 ** 
  

	**	Confidential Treatment Requested 

 EXHIBIT D 
 DOCUMENTATION 
  

					
		 	D-1	  	Certificate of Analysis (514380801)
			
		 	D-2	  	Certificate of Analysis (TFP-03016)
			
		 	D-3	  	Handling Instructions for Clinical Trial Material

  
  

 D-1 Certificate of Analysis (514380801) 
 ** 
  

	**	Confidential Treatment Requested 

 D-2 Certificate of Analysis (TFP-03016) 
 ** 
  

	**	Confidential Treatment Requested 

 D-3 Handling Instructions for Clinical Trial Material 
 ** 
  

	**	Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]